长链非编码RNA STMN1P2在乳腺癌中的作用及机制研究

doi:10.19401/j.cnki.1007-3639.2021.07.006

中国癌症杂志 ›› 2021, Vol. 31 ›› Issue (7): 596-604.doi: 10.19401/j.cnki.1007-3639.2021.07.006

长链非编码RNA STMN1P2在乳腺癌中的作用及机制研究

金优萍，李录英，周　平

复旦大学基础医学院生理与病理生理学系，上海 200032

出版日期:2021-07-30 发布日期:2021-08-04
通信作者: 周　平 E-mail: zping@shmu.edu.cn

A study on the role of long non-coding RNA STMN1P2 in breast cancer and its mechanism

JIN Youping, LI Luying, ZHOU Ping

Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China

Published:2021-07-30 Online:2021-08-04
Contact: ZHOU Ping E-mail: zping@shmu.edu.cn

摘要/Abstract

摘要： 背景与目的：长链非编码RNA（long non-coding RNA，lncRNA）在肿瘤进展中发挥重要调控作用，我们的前期研究通过lncRNA表达谱芯片筛选发现，微管不稳定蛋白1假基因2（stathmin 1 pseudogene 2，STMN1P2）在乳腺癌中高表达，但其生物学功能以及在乳腺癌中的作用尚未见报道。探讨lncRNA STMN1P2在乳腺癌中的作用及其机制。方法：采用实时荧光定量聚合酶链反应（real-time fluorescence quantitative polymerase chain reaction，RTFQ-PCR）在复旦大学附属肿瘤医院收治的27例乳腺癌患者的乳腺癌组织、癌旁组织以及3种乳腺癌细胞系MDA-MB-231、BT-549、MCF-7和人乳腺上皮细胞系MCF-10A中验证STMN1P2的表达水平。下调或上调STMN1P2的表达后，进行transwell、细胞凋亡和细胞周期检测，研究STMN1P2的生物学功能。通过RNA pull-down实验结合蛋白质印迹法（Western blot）挖掘STMN1P2的结合蛋白，探究潜在的分子机制。结果：STMN1P2在乳腺癌组织和细胞系中的表达显著上调（P<0.05）。干扰STMN1P2后，BT-549细胞的迁移能力显著减弱（P<0.05）；过表达STMN1P2后，MDA-MB-231细胞的迁移能力显著增强（P<0.05）。而STMN1P2对细胞凋亡和细胞周期影响不明显。RNA pull-down实验结果显示，核内不均一核糖核蛋白U（heterogeneous nuclear ribonucleoprotein U，hnRNPU）可能为STMN1P2结合蛋白，且hnRNPU的mRNA和蛋白水平均受STMN1P2调控（P<0.05）。挽救实验结果显示，抑制hnRNPU表达能够逆转STMN1P2的促细胞迁移作用（P<0.05）。结论：STMN1P2可能通过结合hnRNPU发挥促进乳腺癌细胞迁移的作用。

关键词: 长链非编码RNA, 乳腺癌, 迁移, 核内不均一核糖核蛋白U

Abstract: Background and purpose: Long non-coding RNA (LncRNA) plays a critical role in the malignant progression of tumors. Former study identified lncRNA stathmin 1 pseudogene 2 (STMN1P2) was aberrantly expressed in breast cancer tissues with microarray. However, the role it executes in breast cancer is still unclear. This study aimed to investigate the expression and function of STMN1P2 in breast cancer cells and its underlying mechanism. Methods: Real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR) was used to verify the expression of STMN1P2 in breast cancer tissues from 27 breast cancer patients who were treated in Fudan University Shanghai Cancer Center and paracancerous tissues, 3 breast cancer cell lines of MDA-MB-231, BT-549, MCF-7 and human mammary epithelial cell line MCF-10A. STMN1P2 levels were downregulated or upregulated, and transwell, cell apoptosis and cell cycle detection assays were performed to study the biological functions of STMN1P2. The binding protein was figured out through RNA pull-down experiment combined with Western blot to discover the underlying mechanism. Results: The expression of STMN1P2 was significantly upregulated in breast cancer tissues and cells (P<0.05). Interference with STMN1P2 decreased the migration of BT-549 cells (P<0.05), and overexpression of STMN1P2 increased the migration of MDA- MB-231 cells (P<0.05). Our results showed that STMN1P2 might not be related to cell apoptosis and cell cycle. RNA pull-down results showed that heterogeneous nuclear ribonucleoprotein U (hnRNPU) might be the binding protein of STMN1P2, and the expression of hnRNPU might be regulated by STMN1P2 (P<0.05). The results of the rescue experiment showed that downregulating hnRNPU expression reversed the effect of STMN1P2 on promoting cell migration (P<0.05). Conclusion: STMN1P2 may promote breast cancer cell migration via binding and interacting with hnRNPU.

Key words: Long non-coding RNA, Breast cancer, Migration, Heterogeneous nuclear ribonucleoprotein U

金优萍, 李录英, 周　平. 长链非编码RNA STMN1P2在乳腺癌中的作用及机制研究[J]. 中国癌症杂志, 2021, 31(7): 596-604.

JIN Youping, LI Luying, ZHOU Ping. A study on the role of long non-coding RNA STMN1P2 in breast cancer and its mechanism[J]. China Oncology, 2021, 31(7): 596-604.

[1]	章箎, 陈佳慧, 林瑾仪, 王妍, 张斯加, 朱玮, 程蕾蕾. 一种新型《乳腺癌治疗相关心血管毒性临床评分表》的价值分析[J]. 中国癌症杂志, 2022, 32(1): 54-60.
[2]	金奕滋, 林明曦, 张剑. DNA损伤应答缺陷作为乳腺癌治疗靶点的研究进展[J]. 中国癌症杂志, 2022, 32(1): 61-67.
[3]	《中国乳腺癌新辅助治疗专家共识（2022年版）》专家组. 中国乳腺癌新辅助治疗专家共识（2022年版）[J]. 中国癌症杂志, 2022, 32(1): 80-89.
[4]	张小艳, 李清祥, 刘　勇, 李　航, 仇丽娟, 封欣然, 谭立明 . HMGB1与乳腺癌患者临床病理学特征及免疫指标的相关性研究[J]. 中国癌症杂志, 2021, 31(9): 783-788.
[5]	曹爱玲, 曹　喆, 周　剑. 多西他赛联合胸腺肽α1对大鼠乳腺癌免疫微环境中Treg数量的影响及其机制研究[J]. 中国癌症杂志, 2021, 31(9): 799-806.
[6]	姚　嘉, 李冠乔, 杨时平, 苏慧銮 . Hsa-miR-98-5p/DKK3信号轴对乳腺癌细胞生物学行为的影响[J]. 中国癌症杂志, 2021, 31(9): 807-816.
[7]	丛斌斌, 王永胜. 激素受体阳性早期乳腺癌治疗现状与挑战[J]. 中国癌症杂志, 2021, 31(8): 689-696.
[8]	杨士鹏, 刘颖, 王馨悦, 杨洋, 全吉淑, 林贞花 . PKLR在胰腺癌中的表达水平及临床病理学意义[J]. 中国癌症杂志, 2021, 31(8): 704-713.
[9]	朱逸晖, 李　婷, 胡夕春. Trastuzumab deruxtecan的临床研究进展及展望——HER2耐药患者的新希望[J]. 中国癌症杂志, 2021, 31(8): 754-761.
[10]	丁高峰, 郭雷鸣, 陆寓非. 乳腺癌患者HER2和BRCA1表达与放疗敏感性的关系研究[J]. 中国癌症杂志, 2021, 31(7): 589-595.
[11]	谢金芳, 曹春雨, 任　雪, 田家俊, 吕亚丰, 黄晓飞 . 萝卜硫素对小鼠乳腺癌4T1细胞上皮-间质转化、增殖和迁移的影响研究[J]. 中国癌症杂志, 2021, 31(7): 605-615.
[12]	曹达龙, 朱文恺, 施国海, 张海梁, 王子良, 叶定伟. PRUNE2点突变影响前列腺癌DU145细胞增殖、凋亡、侵袭和迁移[J]. 中国癌症杂志, 2021, 31(6): 441-446.
[13]	朱俊军, 葛乃建, 杨业发. 恶性肿瘤植入放射性 125 I粒子出现迁移的研究现状与展望[J]. 中国癌症杂志, 2021, 31(4): 257-262.
[14]	乔婷婷, 葛淑静, 罗　渊, 陆承荣, 段连宁 . H2AX磷酸化抑制肺癌细胞发生上皮-间质转化的作用机制[J]. 中国癌症杂志, 2021, 31(4): 277-284.
[15]	曾　峰, 李　丹, 邵鑫鑫, 张能英, 陈星翰, 程晓明 . 基于SEER数据库构建1~2枚淋巴结阳性且乳房全切的老年早期乳腺癌患者不同腋窝手术方式的生存预测模型[J]. 中国癌症杂志, 2021, 31(4): 323-329.

长链非编码RNA STMN1P2在乳腺癌中的作用及机制研究

A study on the role of long non-coding RNA STMN1P2 in breast cancer and its mechanism

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价